Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Teva Pharma Industries Ltd ADR (TEVA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Teva ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
13.23 -0.07    -0.53%
15/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
13.28
+0.05
+0.38%
9:30:41 - Real-time Data
  • Volume: 13,401,641
  • Bid/Ask: 13.26 / 13.29
  • Day's Range: 13.13 - 13.57
Type:  Equity
Market:  United States
Teva ADR 13.23 -0.07 -0.53%

TEVA Balance Sheet

 
Assess the latest Teva balance sheet. Review the company's financial position, assess their current assets, liabilities and shareholder equity across the most recent periods (either quarterly or annually).

Even more advanced TEVA Annual Report data, financial summaries and charts are available for Teva Pharma Industries Ltd ADR investors with their own InvestingPro account.
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 12485 11425 12088 11501
Cash and Short Term Investments 3226 2249 2669 2143
Cash - - - -
Cash & Equivalents 3226 2249 2669 2143
Short Term Investments - - - -
Total Receivables, Net 3408 3385 3539 3435
Accounts Receivables - Trade, Net 3408 3385 3539 3435
Total Inventory 4021 4051 4109 4118
Prepaid Expenses 1255 1168 1228 1253
Other Current Assets, Total 575 572 543 552
Total Assets 43479 42088 43095 43456
Property/Plant/Equipment, Total - Net 6147 6028 6130 6171
Property/Plant/Equipment, Total - Gross 11784 - - -
Accumulated Depreciation, Total -5637 - - -
Goodwill, Net 17177 16885 17118 17799
Intangibles, Net 5387 5525 5738 5964
Long Term Investments 8 - - -
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 463 477 443 449
Other Assets, Total 3000 2986 2691 2807
Total Current Liabilities 12247 11394 11843 10411
Accounts Payable 2602 2280 2508 2381
Payable/Accrued - - - -
Accrued Expenses 5525 5274 5014 4633
Notes Payable/Short Term Debt - 500 - -
Current Port. of LT Debt/Capital Leases 1769 979 1980 1023
Other Current liabilities, Total 2351 2361 2341 2374
Total Liabilities 35353 34577 35387 34845
Total Long Term Debt 18184 18495 18698 19668
Long Term Debt 18161 18495 18698 19668
Capital Lease Obligations 23 - - -
Deferred Income Tax 606 544 534 550
Minority Interest 620 582 656 751
Other Liabilities, Total 3696 3062 3656 3465
Total Equity 8126 7511 7708 8611
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 57 57 57 57
Additional Paid-In Capital 27807 27780 27748 27719
Retained Earnings (Accumulated Deficit) -13534 -13870 -13950 -13086
Treasury Stock - Common -4128 -4128 -4128 -4128
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -2076 -2328 -2019 -1951
Total Liabilities & Shareholders' Equity 43479 42088 43095 43456
Total Common Shares Outstanding 1121.09 1120.97 1120.65 1120.41
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TEVA Price Commentary

Write your thoughts about Teva Pharma Industries Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Rafi Shoev
Rafi Shoev Jan 22, 2024 23:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva 125years of developing new drugs bigest jeneic company andto be leader in biosimilar drugs.
Rafi Shoev
Rafi Shoev Jan 17, 2024 14:23
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva free cash flew aoutsyrnding
Rafi Shoev
Rafi Shoev Jan 16, 2024 15:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
24.02.24 Alboteck and teva .Humira biosimilar on the top of the day.from FDA.finally.
Rafi Shoev
Rafi Shoev Jan 16, 2024 15:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Freecash is very intresting???
Rafi Shoev
Rafi Shoev Jan 16, 2024 15:09
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very atractiv ???
Rafi Shoev
Rafi Shoev Jan 15, 2024 10:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva revenew my hope will be more than 17.5bilions.
Rafi Shoev
Rafi Shoev Jan 12, 2024 19:41
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If your stock is dawn its probably a time to by more.
Rafi Shoev
Rafi Shoev Jan 12, 2024 16:26
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Concidering to sturting by back .
Rafi Shoev
Rafi Shoev Jan 12, 2024 15:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The humira biosomilar wil be agaim changer
Rafi Shoev
Rafi Shoev Jan 12, 2024 14:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jaint phrma is nomber one in tell aviv stock.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email